SS
CORT icon

SBI Securities’s Corcept Therapeutics CORT Stock Holding History

SBI Securities’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.3K Sell
325
-16
-5% -$966 ﹤0.01% 1412
2026
Q1 		$13.7K Buy
341
+166
+95% +$6.21K ﹤0.01% 1605
2025
Q4 		$6.09K Buy
175
+55
+46% +$4.32K ﹤0.01% 1945
2025
Q3 		$9.97K Sell
120
-202
-63% -$14.6K ﹤0.01% 1779
2025
Q2 		$23.6K Buy
322
+300
+1,364% +$21.8K ﹤0.01% 1349
2025
Q1 		$2.51K Buy
22
+17
+340% +$1.03K ﹤0.01% 2195
2024
Q4 		$252 Buy
+5
New +$262 ﹤0.01% 3160

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SBI Securities's CORT Position: Q2 2026 in Review

SBI Securities reduced its Corcept Therapeutics (CORT) stake by 4.7% in Q2 2026, selling an estimated $966 and leaving 325 shares worth $28.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1412.

SBI Securities first reported a position in CORT in Q4 2024 and has held it in 7 quarters since. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • SBI Securities held 325 shares of Corcept Therapeutics worth $28.3K as of Q2 2026.
  • SBI Securities sold 16 Corcept Therapeutics shares in Q2 2026, an estimated $966.
  • Corcept Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #1412 holding.
  • SBI Securities first reported a position in Corcept Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.